- Home
- HURA vs MCRB Comparison
HURA vs MCRB Comparison
Compare HURA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- MCRB
- Stock Information
- Founded
- HURA 2009
- MCRB 2010
- Country
- HURA United States
- MCRB United States
- Employees
- HURA N/A
- MCRB N/A
- Industry
- HURA
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- HURA
- MCRB Health Care
- Exchange
- HURA Nasdaq
- MCRB Nasdaq
- Market Cap
- HURA 103.3M
- MCRB 103.7M
- IPO Year
- HURA N/A
- MCRB 2015
- Fundamental
- Price
- HURA $2.64
- MCRB $14.07
- Analyst Decision
- HURA Strong Buy
- MCRB Hold
- Analyst Count
- HURA 2
- MCRB 4
- Target Price
- HURA $11.50
- MCRB $73.67
- AVG Volume (30 Days)
- HURA 500.9K
- MCRB 149.9K
- Earning Date
- HURA 08-15-2025
- MCRB 08-12-2025
- Dividend Yield
- HURA N/A
- MCRB N/A
- EPS Growth
- HURA N/A
- MCRB N/A
- EPS
- HURA N/A
- MCRB 8.98
- Revenue
- HURA N/A
- MCRB N/A
- Revenue This Year
- HURA N/A
- MCRB N/A
- Revenue Next Year
- HURA $69.15
- MCRB N/A
- P/E Ratio
- HURA N/A
- MCRB $1.70
- Revenue Growth
- HURA N/A
- MCRB N/A
- 52 Week Low
- HURA $1.80
- MCRB $6.53
- 52 Week High
- HURA $9.94
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- MCRB 70.42
- Support Level
- HURA N/A
- MCRB $13.19
- Resistance Level
- HURA N/A
- MCRB $15.98
- Average True Range (ATR)
- HURA 0.00
- MCRB 1.40
- MACD
- HURA 0.00
- MCRB 0.27
- Stochastic Oscillator
- HURA 0.00
- MCRB 72.62
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.